Drug manufacturers have increased their production, and some such as Novo Nordisk have asked the FDA to ban further production of compounded versions of their drugs. If that happens, Lavin says many ...

Novo Nordisk gained approval for Wegovy in China in June, and will initially target Chinese patients willing to pay ...

Novo Nordisk A/S is launching its top-selling Wegovy obesity drug in China at a fraction of the US price, a key step in ...

More than 9million prescriptions for Ozempic and similar weight loss drugs are written every year in the US, estimates ...

Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June. It ...

Novo Nordisk has officially launched its weight loss medication Wegovy in China. This move opens access to over 500 million ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound, according to the AXIACI ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...

Investors are keeping a close eye on Wall Street’s major indices, which are showing a stronger performance on Monday. The ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.